Here’s why Nepal banned 16 Indian pharma companies, including Patanjali’s Divya Pharmaceuticals

Nepal has banned the import of medicines from 16 Indian pharmaceutical companies, including Divya Pharmaceuticals – a subsidiary of yoga guru Ramdev’s Patanjali Yog Peeth – and Cadilla, citing the failure of compliance with the World Health Organisation’s good manufacturing practices.

Nepal’s Department of Drug Administration – the country’s regulatory body for drugs – Tuesday published a list of Indian pharmaceutical companies that didn’t meet the WHO guidelines.

“After inspection of the manufacturing facilities of the pharmaceutical companies, which had applied to export their products to our country, we have published the list of the companies that do not comply with the World Health Organisation’s good manufacturing practices,” Santosh KC, a spokesperson at the department, told to a daily The Kathmandu Post.

According to the report, the department had sent a team of drug inspectors to India in the months of April and July, to inspect the manufacturing facilities of pharmaceutical companies that had applied to supply their products to Nepal.

Good Manufacturing Practices (GMP, also referred to as ‘cGMP’ or ‘current Good Manufacturing Practice’) is the aspect of quality assurance that ensures that medicinal products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the product specification.

More than 100 countries have incorporated the WHO GMP provisions into their national medicines laws, and many more countries have adopted its provisions and approach in defining their own national GMP requirements.

This is not the first time the sale of Indian drugs have come under the scanner in Nepal. In 2019, an import ban was imposed on three Indian medicines, including Zylo-P of Leben Laboratories, Reldine of Real Hygiene and Kelvin of Leben Laboratories

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!